http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015218433-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ba8052a2cec6dcd5293713a6839cd8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate | 2015-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4d23cac1b69a65f8d67a289c5985c3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78956cef9f1b0dc928e6ebac9a34650e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eafdbac9d2f56cf455faa7d9312afa0 |
| publicationDate | 2017-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2015218433-B2 |
| titleOfInvention | Methods and compositions for sleep disorders and other disorders |
| abstract | Use of a particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or 5 more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. |
| priorityDate | 2008-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 390.